News FDA panel backs Ardelyx CKD drug, despite agency concerns While the FDA seems to remain sceptical about the clinical benefits of Ardelyx's chronic kidney disease (CKD) therapy Xphozah – having
News Hard times at Ardelyx as FDA rejects kidney disease drug ten... The FDA has taken a longer than usual look at Ardelyx's regulatory submission for tenapanor, a drug for high blood phosphate levels associated with chronic kidney disease (CKD), and found i
Views & Analysis Ardelyx’s ambition to revolutionise kidney treatment A therapy to treat hyperphosphatemia is moving closer to the market after years of development by California-based company Ardelyx.
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.